TVTX — Travere Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.81bn
- $2.80bn
- $490.73m
Annual income statement for Travere Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 132 | 109 | 145 | 233 | 491 |
| Cost of Revenue | |||||
| Gross Profit | 128 | 105 | 134 | 225 | 480 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 331 | 437 | 533 | 557 | 554 |
| Operating Profit | -199 | -327 | -388 | -324 | -62.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -217 | -331 | -376 | -321 | -49.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -217 | -331 | -376 | -321 | -50.3 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -180 | -278 | -111 | -322 | -25.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -180 | -278 | -111 | -322 | -25.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.63 | -5.12 | -4.97 | -3.22 | -0.563 |